Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval

Stock Track

05/19

BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.

The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.

Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1172120087"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172120087\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172120087?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172120087","market":"sg","top_or_hot":-1,"title":"Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval","media":"Stock Track","content":"<p>BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.</p><p>The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.</p><p>Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BOAN BIOTECH Soars 14.97% Intraday on Share Buyback Plan and Macau Drug Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-19 10:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.</p><p>The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.</p><p>Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06955","symbol_name":"博安生物","start_time":0,"source_url":"","article_id":"1172120087","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172120087","pubTimestamp":1779159162,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.The company announced a share repurchase plan, with...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06955":"博安生物"},"translate_title":"个股赛道|博安生物盘中大涨14.97%因股份回购计划及澳门药物获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06955":1},"content_text":"BOAN BIOTECH's stock price soared 14.97% during the intraday trading session on Tuesday, driven by two significant corporate developments.The company announced a share repurchase plan, with authorization to buy back shares on the open market with a total value not exceeding HK$200 million. Such buyback programs are typically viewed positively by investors as they can signal management's confidence in the company's value and potentially boost earnings per share.Furthermore, BOAN BIOTECH received marketing approval from the Macau Special Administrative Region for its independently developed Dulaglutide Injection (BA5101), indicated for glycemic control in adult patients with type 2 diabetes. The drug is recognized as the first and only biosimilar of Trulicity® approved globally and marks the first domestically developed dulaglutide injection approved in Macau. The product has also received clearance to initiate clinical trials in the United States, laying groundwork for international market expansion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}